MA52810A - Procédés d'utilisation de cd24 pour la prévention et le traitement de la maladie du greffon contre l'hôte et de la mucosite - Google Patents
Procédés d'utilisation de cd24 pour la prévention et le traitement de la maladie du greffon contre l'hôte et de la mucositeInfo
- Publication number
- MA52810A MA52810A MA052810A MA52810A MA52810A MA 52810 A MA52810 A MA 52810A MA 052810 A MA052810 A MA 052810A MA 52810 A MA52810 A MA 52810A MA 52810 A MA52810 A MA 52810A
- Authority
- MA
- Morocco
- Prior art keywords
- mucositis
- prevention
- treatment
- methods
- graft disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862680218P | 2018-06-04 | 2018-06-04 | |
US201862739742P | 2018-10-01 | 2018-10-01 | |
US201862739719P | 2018-10-01 | 2018-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52810A true MA52810A (fr) | 2021-04-14 |
Family
ID=68770596
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052811A MA52811A (fr) | 2018-06-04 | 2019-06-03 | Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie |
MA052810A MA52810A (fr) | 2018-06-04 | 2019-06-03 | Procédés d'utilisation de cd24 pour la prévention et le traitement de la maladie du greffon contre l'hôte et de la mucosite |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052811A MA52811A (fr) | 2018-06-04 | 2019-06-03 | Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie |
Country Status (15)
Country | Link |
---|---|
US (2) | US20210228680A1 (fr) |
EP (2) | EP3802583A4 (fr) |
JP (2) | JP2021527056A (fr) |
KR (2) | KR20210018294A (fr) |
CN (2) | CN112512640A (fr) |
AU (2) | AU2019282044A1 (fr) |
BR (2) | BR112020024659A2 (fr) |
CA (2) | CA3102374A1 (fr) |
CL (2) | CL2020003168A1 (fr) |
IL (2) | IL279205A (fr) |
MA (2) | MA52811A (fr) |
MX (2) | MX2020013100A (fr) |
SG (2) | SG11202011964SA (fr) |
TW (2) | TW202012015A (fr) |
WO (2) | WO2019236472A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112512640A (zh) * | 2018-06-04 | 2021-03-16 | 肿瘤免疫股份有限公司 | Cd24用于预防和治疗移植物抗宿主病和粘膜炎的使用方法 |
EP4103217A4 (fr) * | 2020-02-10 | 2024-03-13 | Oncoimmune Inc. | Procédés d'utilisation de cd24 soluble pour le traitement de la pneumonie virale |
WO2023205742A1 (fr) * | 2022-04-20 | 2023-10-26 | OncoC4, Inc. | Protéines cd24 mutantes et leurs utilisations pour la prophylaxie et le traitement du cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
CA2705353C (fr) | 2007-11-14 | 2017-07-25 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Procedes de traitement du cancer a l'aide d'anticorps anti-cd24 |
US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
PL2563385T3 (pl) * | 2010-04-28 | 2018-04-30 | Oncoimmune Inc. | Sposoby i zastosowanie rozpuszczalnego CD24 do terapii reumatoidalnego zapalenia stawów |
CN102250828B (zh) * | 2010-11-10 | 2014-11-05 | 北京大学 | Cd24及cd24抗体的新用途 |
WO2013158959A1 (fr) * | 2012-04-19 | 2013-10-24 | Tarix Pharmaceuticals Ltd. | Compositions et procédés pour le traitement de la maladie du greffon contre l'hôte |
WO2016073704A1 (fr) * | 2014-11-06 | 2016-05-12 | Children's Research Institute, Children's National Medical Center | Composés immunothérapeutiques pour le cancer et les maladies auto-immunes |
AU2016258084B2 (en) * | 2015-05-07 | 2020-01-30 | Oncoimmune, Inc. | Use of CD24 for lowering low-density lipoprotein cholesterol levels |
WO2017136492A1 (fr) * | 2016-02-02 | 2017-08-10 | Oncoimmune, Inc. | Utilisation de protéines cd24 pour traiter des pathologies à déficience en leptine |
CN112512640A (zh) * | 2018-06-04 | 2021-03-16 | 肿瘤免疫股份有限公司 | Cd24用于预防和治疗移植物抗宿主病和粘膜炎的使用方法 |
WO2021142336A1 (fr) * | 2020-01-08 | 2021-07-15 | Puretech Lyt, Inc. | Compositions vésiculaires pour une administration par voie orale |
-
2019
- 2019-06-03 CN CN201980050232.9A patent/CN112512640A/zh active Pending
- 2019-06-03 BR BR112020024659-0A patent/BR112020024659A2/pt not_active Application Discontinuation
- 2019-06-03 CA CA3102374A patent/CA3102374A1/fr not_active Abandoned
- 2019-06-03 EP EP19815874.3A patent/EP3802583A4/fr active Pending
- 2019-06-03 EP EP19815487.4A patent/EP3801773A4/fr not_active Withdrawn
- 2019-06-03 CN CN201980049870.9A patent/CN112752766A/zh active Pending
- 2019-06-03 TW TW108119239A patent/TW202012015A/zh unknown
- 2019-06-03 MA MA052811A patent/MA52811A/fr unknown
- 2019-06-03 US US15/734,961 patent/US20210228680A1/en not_active Abandoned
- 2019-06-03 TW TW108119240A patent/TW202015753A/zh unknown
- 2019-06-03 WO PCT/US2019/035200 patent/WO2019236472A1/fr unknown
- 2019-06-03 SG SG11202011964SA patent/SG11202011964SA/en unknown
- 2019-06-03 SG SG11202011963UA patent/SG11202011963UA/en unknown
- 2019-06-03 JP JP2020567863A patent/JP2021527056A/ja active Pending
- 2019-06-03 KR KR1020207035971A patent/KR20210018294A/ko unknown
- 2019-06-03 BR BR112020024683-2A patent/BR112020024683A2/pt not_active Application Discontinuation
- 2019-06-03 MX MX2020013100A patent/MX2020013100A/es unknown
- 2019-06-03 MX MX2020013103A patent/MX2020013103A/es unknown
- 2019-06-03 KR KR1020207036790A patent/KR20210021317A/ko unknown
- 2019-06-03 CA CA3102372A patent/CA3102372A1/fr active Pending
- 2019-06-03 MA MA052810A patent/MA52810A/fr unknown
- 2019-06-03 AU AU2019282044A patent/AU2019282044A1/en not_active Abandoned
- 2019-06-03 US US15/734,957 patent/US11911441B2/en active Active
- 2019-06-03 WO PCT/US2019/035205 patent/WO2019236474A1/fr unknown
- 2019-06-03 AU AU2019282530A patent/AU2019282530A1/en not_active Abandoned
- 2019-06-03 JP JP2020568311A patent/JP2021527066A/ja active Pending
-
2020
- 2020-12-03 IL IL279205A patent/IL279205A/en unknown
- 2020-12-03 IL IL279204A patent/IL279204A/en unknown
- 2020-12-04 CL CL2020003168A patent/CL2020003168A1/es unknown
- 2020-12-04 CL CL2020003169A patent/CL2020003169A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202011964SA (en) | 2020-12-30 |
AU2019282044A1 (en) | 2021-01-07 |
CA3102374A1 (fr) | 2019-12-12 |
BR112020024683A2 (pt) | 2021-03-09 |
MA52811A (fr) | 2022-03-16 |
MX2020013100A (es) | 2021-02-17 |
MX2020013103A (es) | 2021-05-12 |
IL279205A (en) | 2021-01-31 |
WO2019236474A1 (fr) | 2019-12-12 |
AU2019282530A1 (en) | 2021-01-07 |
EP3802583A1 (fr) | 2021-04-14 |
SG11202011963UA (en) | 2020-12-30 |
KR20210021317A (ko) | 2021-02-25 |
TW202015753A (zh) | 2020-05-01 |
CN112752766A (zh) | 2021-05-04 |
KR20210018294A (ko) | 2021-02-17 |
CL2020003168A1 (es) | 2021-06-11 |
JP2021527066A (ja) | 2021-10-11 |
EP3801773A4 (fr) | 2022-03-16 |
EP3801773A1 (fr) | 2021-04-14 |
EP3802583A4 (fr) | 2022-03-16 |
US20210268061A1 (en) | 2021-09-02 |
US11911441B2 (en) | 2024-02-27 |
CL2020003169A1 (es) | 2021-06-11 |
CA3102372A1 (fr) | 2019-12-12 |
TW202012015A (zh) | 2020-04-01 |
BR112020024659A2 (pt) | 2021-03-09 |
IL279204A (en) | 2021-01-31 |
JP2021527056A (ja) | 2021-10-11 |
CN112512640A (zh) | 2021-03-16 |
WO2019236472A1 (fr) | 2019-12-12 |
US20210228680A1 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA52810A (fr) | Procédés d'utilisation de cd24 pour la prévention et le traitement de la maladie du greffon contre l'hôte et de la mucosite | |
MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
MA50417A (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
MA45089A (fr) | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes | |
MA53558A (fr) | Compositions et procédés pour le traitement d'infections virales | |
MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA52971A (fr) | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle | |
MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
MA53739A (fr) | Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés | |
MA53252A (fr) | Thérapie génique non perturbatrice pour le traitement d'un mma | |
MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
MA54909A (fr) | Procédés et appareil de traitement d'eau | |
MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
EP3768262A4 (fr) | Compositions et méthodes pour traiter une maladie inflammatoire de l'intestin et des maladies et des affections provoquées par ou associées à fusobacterium |